News
Article
Author(s):
Following Valisure’s Citizen’s Petition to the US Food and Drug Administration, we are recapping recent years of regulatory action regarding benzene and carbomers.
Last week, New Haven, Connecticut-based independent laboratory Valisure LLC announced1 it had filed a Citizen's Petition2 to the US Food and Drug Administration (FDA) regarding its findings of high levels of benzene in benzoyl peroxide (BPO)- containing skin care products.
An initial stability study tested 5 products at temperatures of 37°C, 50°C and 70°C. Investigators conducted addition incubation testing with 66 BPO products, including creams, lotions, gels, and washes, commonly available over the counter or through prescription, at 50°C and 70°C for 18 days each per respective temperature.2
Including large name-brand consumer products, some of the testing products on the higher end of the spectrum contained more than 1000 parts per million of benzene. Presently, US FDA guidelines allow up to 2 parts per million of benzene.2
While clinicians and consumers alike await comment from the FDA regarding these findings, it should be noted that the FDA has a long history of involvement and regulation of benzene and carbomers that contain it. We recap recent involvement below.
This timeline will be updated as more benzene-related news comes forward. Please note: You may need to hover and scroll over the timeline to read the full summary of each event. You can also click here to view the timeline in a new window.
References